Search Page

1

Cite

Share

Challenges and Opportunities for Biomarker Validation.

Hey SP, D'Andrea E, Jung EH, Tessema F, Luo J, Gyawali B, Kesselheim AS. Hey SP, et al. J Law Med Ethics. 2019 Sep;47(3):357-361. doi: 10.1177/1073110519876162. J Law Med Ethics. 2019. PMID: 31560620

Cite

Share

2

Cite

Share

Insulin access and affordability in the USA: anticipating the first interchangeable insulin product.

Luo J, Kesselheim AS, Sarpatwari A. Luo J, et al. Lancet Diabetes Endocrinol. 2020 May;8(5):360-362. doi: 10.1016/S2213-8587(20)30105-4. Epub 2020 Mar 20. Lancet Diabetes Endocrinol. 2020. PMID: 32203681 No abstract available.

Cite

Share

3

Cite

Share

Inaccurate Reporting of Insulin Reimbursement-Reply.

Luo J, Avorn J, Kesselheim AS. Luo J, et al. JAMA Intern Med. 2016 Mar;176(3):408-9. doi: 10.1001/jamainternmed.2015.8101. JAMA Intern Med. 2016. PMID: 26954041 No abstract available.

Cite

Share

4

Cite

Share

Variation in Prescription Drug Prices by Retail Pharmacy Type: A National Cross-sectional Study.

Luo J, Kulldorff M, Sarpatwari A, Pawar A, Kesselheim AS. Luo J, et al. Ann Intern Med. 2019 Nov 5;171(9):605-611. doi: 10.7326/M18-1138. Epub 2019 Oct 1. Ann Intern Med. 2019. PMID: 31569218

Cite

Share

5

Cite

Share

Delayed Generic Market Saturation After Patent Expiration-A Billion-Dollar Problem.

Luo J, Kesselheim AS. Luo J, et al. JAMA Intern Med. 2018 May 1;178(5):721-722. doi: 10.1001/jamainternmed.2018.0989. JAMA Intern Med. 2018. PMID: 29801126 No abstract available.

Cite

Share

6

Cite

Share

Strategies to improve the affordability of insulin in the USA.

Luo J, Kesselheim AS, Greene J, Lipska KJ. Luo J, et al. Lancet Diabetes Endocrinol. 2017 Mar;5(3):158-159. doi: 10.1016/S2213-8587(17)30041-4. Epub 2017 Feb 9. Lancet Diabetes Endocrinol. 2017. PMID: 28189654 No abstract available.

Cite

Share

7

Cite

Share

Cost-effectiveness of Statin Therapy for ASCVD.

Luo J, Kesselheim AS. Luo J, et al. JAMA. 2015 Nov 24;314(20):2191. doi: 10.1001/jama.2015.12919. JAMA. 2015. PMID: 26599189 No abstract available.

Cite

Share

8

Cite

Share

Insulin patents and market exclusivities: unresolved issues--Authors' reply.

Luo J, Kesselheim AS. Luo J, et al. Lancet Diabetes Endocrinol. 2016 Feb;4(2):98-9. doi: 10.1016/S2213-8587(15)00494-5. Lancet Diabetes Endocrinol. 2016. PMID: 26825232 No abstract available.

Cite

Share

9

Cite

Share

Rates and Costs of Dispensing Naloxone to Patients at High Risk for Opioid Overdose in the United States, 2014-2018.

Barenie RE, Gagne JJ, Kesselheim AS, Pawar A, Tong A, Luo J, Bateman BT. Barenie RE, et al. Drug Saf. 2020 Jul;43(7):669-675. doi: 10.1007/s40264-020-00923-6. Drug Saf. 2020. PMID: 32180134

Cite

Share

10

Cite

Share

Implementation of a Health Plan Program for Switching From Analogue to Human Insulin and Glycemic Control Among Medicare Beneficiaries With Type 2 Diabetes.

Luo J, Khan NF, Manetti T, Rose J, Kaloghlian A, Gadhe B, Jain SH, Gagne JJ, Kesselheim AS. Luo J, et al. JAMA. 2019 Jan 29;321(4):374-384. doi: 10.1001/jama.2018.21364. JAMA. 2019. PMID: 30694321 Free PMC article.

Cite

Share